XBiotech

XBiotech Inc. is a clinical-stage biotechnology company headquartered in Austin, Texas, focused on discovering and developing therapies based on naturally occurring human antibodies. Its research model seeks to identify antibodies present in people who have mounted effective immune responses and then develop those antibodies as purified, manufacturable medicines. The company has applied this approach to diseases in which inflammation is believed to contribute to disease progression, including cancer, dermatological conditions, rheumatological disorders, and infectious diseases. Founded by John Simard in Vancouver, Canada, in 2005, XBiotech moved its headquarters to Austin in 2008. The company built its identity around human-derived antibody therapeutics rather than conventional small-molecule drug discovery. Its best-known clinical programs have targeted interleukin-1 alpha, or IL-1α, a cytokine associated with tumor-promoting inflammation and several inflammatory diseases. The company’s leading historical oncology candidate was MABp1, later known as bermekimab and marketed in development under the name Xilonix. The program was designed to inhibit tumor-associated inflammation in advanced colorectal cancer and was studied in other disease areas as well. XBiotech became a Nasdaq-listed company in September 2016 under the ticker XBIT. Its initial public offering raised approximately $70.9 million, with proceeds intended to support later-stage clinical development, construction of a research and manufacturing facility in southeast Austin, earlier-stage programs, and general corporate activities. In 2017, the company completed a registered direct offering of more than $30 million and opened a 40,000-square-foot production facility in Austin. These investments reflected an effort to maintain internal capabilities for antibody production and clinical development. The company’s development history includes both regulatory progress and setbacks. Xilonix received United States Food and Drug Administration Fast Track designation in 2012 and advanced to Phase 3 testing in the United States and Europe by 2016. XBiotech later reported that European regulators had extended the timetable for addressing deficiencies in the product’s registration application. In 2017, the company began a clinical study evaluating MABp1 in combination with ONIVYDE and fluorouracil plus folinic acid for pancreatic cancer. In December 2019, XBiotech sold rights to bermekimab for dermatological indications to Janssen Pharmaceutical, a Johnson & Johnson subsidiary. The announced transaction was valued at $750 million upfront, with potential milestone payments of up to $600 million. Johnson & Johnson subsequently discontinued development of bermekimab for eczema in 2022 and recorded a pretax impairment charge of $610 million; by January 2023, development for hidradenitis suppurativa was also reported as discontinued. These events materially changed the commercial outlook for XBiotech’s most prominent antibody program, although the company’s broader platform and pipeline remained centered on human-derived antibody discovery. During the COVID-19 pandemic, XBiotech worked with BioBridge Global and the South Texas Blood & Tissue Center to apply its antibody-screening technology to convalescent samples. The collaboration sought to identify naturally occurring antibodies with activity against SARS-CoV-2. XBiotech also pursued a potential COVID-19 therapy by isolating antibody genes from convalescent plasma with the aim of producing a purified, scalable antibody medicine. Overall, XBiotech is positioned as a platform-oriented biopharmaceutical company whose principal differentiator is the discovery and development of human-derived antibodies for diseases involving pathological inflammation.

XBiotech was established in Vancouver, Canada, in 2005 by John Simard. The company was founded around the idea that effective human immune responses could provide a source of therapeutic antibodies. Rather than relying exclusively on engineered or laboratory-designed molecules, XBiotech sought to identify antibodies occurring naturally in people who had successfully controlled particular disease processes. These antibodies could then be characterized, reproduced, and developed as biological medicines. In 2008, XBiotech relocated its headquarters to Austin, Texas. The move placed the company within a growing biotechnology and medical research ecosystem and supported the development of internal research and manufacturing capabilities. Its principal scientific focus became human-derived antibody therapies for diseases involving inflammation, including cancer, rheumatological disease, dermatological conditions, and infection. The company’s most visible historical program was MABp1, an antibody directed against interleukin-1 alpha. The candidate was subsequently associated with the names bermekimab and Xilonix in different development and indication contexts. In oncology, Xilonix was investigated as a treatment for advanced colorectal cancer. The therapeutic rationale was that tumor-associated inflammation can support tumor growth and metastasis; blocking IL-1α was therefore intended to interfere with that inflammatory environment. The United States Food and Drug Administration granted Xilonix Fast Track designation in 2012. By 2016, the candidate had entered Phase 3 studies in both the United States and Europe. XBiotech became a public company in September 2016 through an initial public offering on Nasdaq under the symbol XBIT. The offering raised approximately $70.9 million. According to the company’s stated plans, about $42 million was directed toward later-stage trials for a leading cancer program and construction of a new manufacturing and research facility in southeast Austin. Additional proceeds were reserved for earlier-stage clinical programs and general corporate needs. In March 2017, XBiotech announced a registered direct offering that raised more than $30 million through the sale of common shares at $13 per share. Later that year, the company opened a 40,000-square-foot production facility in southeast Austin. The Xilonix regulatory process encountered difficulties. In February 2017, XBiotech reported in a filing with the United States Securities and Exchange Commission that European regulators had granted additional time for the company to respond to deficiencies identified in the registration application. The company expected to respond by March 22 of that year. The episode illustrated the regulatory uncertainty associated with advancing a first-in-class biologic through late-stage development. XBiotech continued to test MABp1 in additional settings. In October 2017, it enrolled the first patient in a study combining the antibody with ONIVYDE and fluorouracil plus folinic acid for pancreatic cancer. This work extended the company’s exploration of IL-1α inhibition beyond colorectal cancer and reflected its broader strategy of applying one antibody platform to multiple inflammatory disease environments. A major corporate turning point occurred in December 2019, when XBiotech sold bermekimab rights for dermatological conditions to Janssen Pharmaceutical, a Johnson & Johnson subsidiary. The transaction was announced with $750 million in upfront consideration and potential milestone payments of up to $600 million, making the possible aggregate value as high as $1.35 billion if all milestones were achieved. The deal transferred responsibility for the relevant dermatology development programs to Janssen while giving XBiotech access to substantial transaction proceeds and future contingent economics. The program later suffered setbacks under Johnson & Johnson. In February 2022, Johnson & Johnson discontinued bermekimab development for eczema and recorded a $610 million pretax impairment charge. By January 2023, bermekimab was no longer being developed for hidradenitis suppurativa. These decisions reduced the near-term commercial prospects of the asset, although they did not erase the significance of XBiotech’s antibody discovery and development platform. During the COVID-19 pandemic, XBiotech collaborated with BioBridge Global and the South Texas Blood & Tissue Center. The collaboration made use of XBiotech’s antibody-screening technology to identify naturally occurring antibodies in people who had recovered from COVID-19 and that showed activity against the virus. XBiotech also pursued a therapeutic candidate by isolating specific antibodies and their genes from convalescent plasma, with the goal of creating a purified antibody product that could be manufactured at scale. XBiotech’s history therefore combines platform-based antibody discovery, late-stage clinical development, public-market financing, internal manufacturing investment, licensing and acquisition activity, and the clinical and regulatory risks typical of biotechnology. Its public identity remains tied to natural human-derived antibodies and to the effort to translate those antibodies into treatments for inflammation-driven disease.

• 2022

  Eczema development of bermekimab is discontinued

  [1]XBiotechen.wikipedia.org

  Johnson & Johnson discontinued the eczema program and recorded a $610 million pretax impairment charge.

• 2019

  Bermekimab dermatology transaction with Janssen

  [1]XBiotechen.wikipedia.org

  Janssen acquired rights to bermekimab for dermatological indications in a deal announced at $750 million upfront plus potential milestones.

• 2017

  Austin manufacturing facility opens

  [1]XBiotechen.wikipedia.org

  XBiotech opened a 40,000-square-foot production facility in southeast Austin.

• 2016

  Nasdaq initial public offering

  [1]XBiotechen.wikipedia.org

  XBiotech listed on Nasdaq as XBIT and raised approximately $70.9 million in its initial public offering.

• 2012

  Xilonix receives FDA Fast Track designation

  [1]XBiotechen.wikipedia.org

  The company’s IL-1α-targeting oncology candidate received Fast Track designation from the United States Food and Drug Administration.

• 2008

  Headquarters move to Austin

  [1]XBiotechen.wikipedia.org

  The company relocated its headquarters from Vancouver to Austin, Texas.

• 2005

  XBiotech is founded in Vancouver

  [1]XBiotechen.wikipedia.org

  John Simard founded XBiotech in Vancouver, Canada, to develop therapeutics based on naturally occurring human antibodies.

A platform-oriented biopharmaceutical company specializing in naturally occurring human antibodies, particularly antibody therapies aimed at disease-associated inflammation.

• Human-derived monoclonal antibody candidate

  Bermekimab

  Bermekimab is XBiotech’s principal historical antibody candidate and targets interleukin-1 alpha, a mediator associated with inflammatory disease. It was investigated across oncology, dermatology, and other inflammatory indications. Janssen acquired rights for dermatological uses in 2019, but later discontinued development for eczema and hidradenitis suppurativa.

• Oncology antibody candidate

  MABp1

  MABp1 is an IL-1α-targeting antibody studied by XBiotech in cancer and inflammatory disease. The candidate was evaluated in advanced colorectal cancer and later entered a combination study with ONIVYDE, fluorouracil, and folinic acid for pancreatic cancer.

• Oncology biologic candidate

  Xilonix

  Xilonix was the development name associated with XBiotech’s IL-1α antibody program for advanced colorectal cancer. The candidate was intended to reduce tumor-associated inflammation and thereby inhibit mechanisms linked to tumor growth and metastasis. It received FDA Fast Track designation and reached Phase 3 development in the United States and Europe.

• 2020COVID-19 natural antibody screening collaboration

  United States

  XBiotech worked with BioBridge Global and the South Texas Blood & Tissue Center to use antibody-screening technology on convalescent samples and identify naturally occurring antibodies active against SARS-CoV-2.

  Outcome. The initiative supported identification of candidate natural antibodies and complemented XBiotech’s effort to develop a purified, mass-producible COVID-19 antibody therapy.

  Source

• 2020

  Apply natural-antibody platform to COVID-19Strategy

  Background

  The COVID-19 pandemic created demand for antibody screening and potential antibody-based treatments.

  Action taken

  XBiotech screened convalescent samples for effective antibodies and pursued isolation of antibody genes for a scalable purified therapeutic candidate.

  Aftermath

  The work broadened the public application of XBiotech’s human-derived antibody platform beyond its established oncology and inflammatory programs.

  Source

• 2019

  Sell dermatology rights to bermekimab to JanssenM&A

  Background

  XBiotech sought to monetize and advance bermekimab’s dermatology applications through a transaction with a large pharmaceutical partner.

  Action taken

  Janssen Pharmaceutical acquired the relevant rights in a transaction announced at $750 million upfront, with potential milestone payments of up to $600 million.

  Aftermath

  Johnson & Johnson later discontinued the eczema program in 2022 and no longer pursued hidradenitis suppurativa development by January 2023.

  Transaction consideration. $750 million upfront; up to $600 million in potential milestones (December 2019)

  Source

• 2016

  Use IPO proceeds to expand clinical development and manufacturingStrategy

  Background

  After its Nasdaq offering, XBiotech needed capital for later-stage trials, early research programs, and internal production infrastructure.

  Action taken

  The company allocated approximately $42 million toward later-stage cancer trials and construction of a research and manufacturing facility, with the balance supporting earlier programs and corporate purposes.

  Aftermath

  XBiotech subsequently opened a 40,000-square-foot production facility in Austin in 2017.

  Initial public offering proceeds. $70.9 million raised (September 2016)

  Source

• 2020.01.01

  Janssen completes acquisition of bermekimab rights[3]Janssen完成对bermekimab权利的收购biospectrumindia.com

  The Janssen Pharmaceutical Companies of Johnson & Johnson completed the acquisition from XBiotech of all rights to investigational bermekimab, along with certain employees, for $750 million.

Read more

1. 1XBiotechen.wikipedia.org
2. 2XBiotech corporate websitexbiotech.com
3. 3Janssen完成对bermekimab权利的收购biospectrumindia.com